What caused the significant EPS miss in Q4 2023 for NTRB?
4/9/2025 12:24am
The significant EPS miss in Q4 2023 for Nutriband Inc. (NTRB) cannot be attributed to the developments of its lead product, AVERSA fentanyl, nor to the partnership with KT Tape, nor to the potential market for AVERSA buprenorphine, nor to the transdermal technology developments. These factors might have positive impacts on the company's future growth, but they cannot be the reason for the EPS miss in the last quarter of 2023. Therefore, the EPS miss might be related to other factors such as market conditions, competition, or internal management issues. Further information is needed to analyze the reasons behind it.